ArticleInternational journal of cancer2009
Endoglin (CD105) as a urinary and serum marker of prostate cancer.
Article in International journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 61 citations in OpenAlex.
- Unveiling the Dichotomy of Urinary Proteins: Diagnostic Insights into Breast and Prostate Cancer and Their Roles.Proteomes · 2023Review
- CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Generation ofActa pharmaceutica Sinica. B · 2022Article
- The role of endoglin and its soluble form in pathogenesis of preeclampsia.Molecular and cellular biochemistry · 2022Review
- Can serum endoglin be used to improve the diagnostic performance in prostate cancer?World journal of urology · 2021Article
- Endoglin in the Spotlight to Treat Cancer.International journal of molecular sciences · 2021Review
- Soluble Endoglin (sCD105) as a Novel Biomarker for Detecting Aggressive Prostate Cancer.Anticancer research · 2020Article
- Soluble CD105 is prognostic of disease recurrence in prostate cancer patients.Endocrine-related cancer · 2020Article
- Approaches to urinary detection of prostate cancer.Prostate cancer and prostatic diseases · 2019Review
- Review
- Endoglin in liver fibrogenesis: Bridging basic science and clinical practice.World journal of biological chemistry · 2014Review
- Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Current status of biomarkers for prostate cancer.International journal of molecular sciences · 2013Review
- Toward the detection of prostate cancer in urine: a critical analysis.The Journal of urology · 2013Review
- Angiogenesis and lymphangiogenesis in the spectrum of leprosy and its reactional forms.PloS one · 2013Observational
- Tumor markers in prostate cancer I: blood-based markers.Acta oncologica (Stockholm, Sweden) · 2011Review
- Endoglin suppresses human prostate cancer metastasis.Clinical & experimental metastasis · 2011Article
- Urine markers and prostate cancer.Central European journal of urology · 2011Review
- [Value of biomarkers in urology].Der Urologe. Ausg. A · 2010Review
- Transforming Growth Factor-Beta 1 and Endoglin Levels in Congenital Solitary Functioning Kidney.Indian journal of nephrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
We have previously shown that endoglin (CD105) is upregulated in prostatic fluid of men with large volume prostate cancer. We chose to assess endoglin levels in urine and serum from men with prostate cancer or at increased risk for the disease: Urine samples were collected after digital rectal examination (DRE) from 99 men whose cancer status was confirmed by biopsy, and serum samples were collected from 20 men without prostate cancer at low risk for the disease and from 69 men diagnosed with prostate cancer that subsequently underwent radical prostatectomy (30 pT2, 39 pT3). Endoglin levels were assessed by ELISA. Urinary endoglin was elevated in men with biopsy-positive prostate cancer compared to biopsy-negative men (p=0.0014). Urinary endoglin levels in men with prostate cancer correlated with radical prostatectomy tumor volume. The area under the receiver operating characteristic (ROC) curve was 0.72 for urinary endoglin and 0.50 for serum prostate-specific antigen (PSA; sensitivity for cancer detection 73%, specificity 63%). There were no differences in serum endoglin between normal and cancer cases, but there were increases in serum endoglin in non-organ confined (NOC, pT3+) versus organ-confined (OC, pT2) cases (p=0.0004). The area under the ROC curve was 0.75 for serum endoglin and 0.63 for PSA for predicting NOC status, with a sensitivity of 67% and a specificity of 80%. In conclusion, elevations in post-DRE urinary endoglin suggest there may be value in further studying endoglin as a urinary biomarker of prostate cancer. Endoglin levels in both urine and serum may aid in prostate cancer detection and prognostication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.